Novo Nordisk Shares Seem Undervalued Ahead of Key Events -- Market Talk

Dow Jones

Yesterday

1150 GMT - Novo Nordisk shares have continued to be punished on lower near-term growth expectations, but risk-off sentiment seems overdone with key events coming up in the near-term, Deutsche Bank analyst Emmanuel Papadakis writes. The Danish pharmaceutical company is expected to soon announce results from a study into its semaglutide drug on Alzheimer's disease and launch its Wegovy weight-loss pill, among other things. While acknowledging that momentum is extremely challenging and there may be more downside to come, Deutsche Bank thinks the risk-reward calculus is disproportionate at present levels. It lowers its share target price to 475 Danish kroner from 600 kroner but retains its buy rating. Shares rise 2.6% to 302.30 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 11, 2025 06:50 ET (11:50 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582653633"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582653633\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582653633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582653633","market":"fut","top_or_hot":-1,"title":"Novo Nordisk Shares Seem Undervalued Ahead of Key Events -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1150 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> shares have continued to be punished on lower near-term growth expectations, but risk-off sentiment seems overdone with key events coming up in the near-term, Deutsche Bank analyst Emmanuel Papadakis writes. The Danish pharmaceutical company is expected to soon announce results from a study into its semaglutide drug on Alzheimer's disease and launch its Wegovy weight-loss pill, among other things. While acknowledging that momentum is extremely challenging and there may be more downside to come, Deutsche Bank thinks the risk-reward calculus is disproportionate at present levels. It lowers its share target price to 475 Danish kroner from 600 kroner but retains its buy rating. Shares rise 2.6% to 302.30 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 06:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Shares Seem Undervalued Ahead of Key Events -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Shares Seem Undervalued Ahead of Key Events -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-11 19:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1150 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> shares have continued to be punished on lower near-term growth expectations, but risk-off sentiment seems overdone with key events coming up in the near-term, Deutsche Bank analyst Emmanuel Papadakis writes. The Danish pharmaceutical company is expected to soon announce results from a study into its semaglutide drug on Alzheimer's disease and launch its Wegovy weight-loss pill, among other things. While acknowledging that momentum is extremely challenging and there may be more downside to come, Deutsche Bank thinks the risk-reward calculus is disproportionate at present levels. It lowers its share target price to 475 Danish kroner from 600 kroner but retains its buy rating. Shares rise 2.6% to 302.30 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 06:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582653633","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582653633","pubTimestamp":1762861800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1150 GMT - Novo Nordisk shares have continued to be punished on lower near-term growth expectations, but risk-off sentiment seems overdone with key events coming up in the near-term, Deutsche Bank analyst Emmanuel Papadakis writes. The Danish pharmaceutical company is expected to soon announce results from a study into its semaglutide drug on Alzheimer's disease and launch its Wegovy weight-loss pill, among other things. While acknowledging that momentum is extremely challenging and there may be more downside to come, Deutsche Bank thinks the risk-reward calculus is disproportionate at present levels. It lowers its share target price to 475 Danish kroner from 600 kroner but retains its buy rating. Shares rise 2.6% to 302.30 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","BK4599":"减肥药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德股价在关键事件发生前似乎被低估——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5},"content_text":"1150 GMT - Novo Nordisk shares have continued to be punished on lower near-term growth expectations, but risk-off sentiment seems overdone with key events coming up in the near-term, Deutsche Bank analyst Emmanuel Papadakis writes. The Danish pharmaceutical company is expected to soon announce results from a study into its semaglutide drug on Alzheimer's disease and launch its Wegovy weight-loss pill, among other things. While acknowledging that momentum is extremely challenging and there may be more downside to come, Deutsche Bank thinks the risk-reward calculus is disproportionate at present levels. It lowers its share target price to 475 Danish kroner from 600 kroner but retains its buy rating. Shares rise 2.6% to 302.30 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 06:50 ET (11:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}